Thursday January 18th 2018

[Comment] New treatments for multiple sclerosis: at what long-term risk?

Since 1993, eight different classes of disease-modifying therapies for relapsing-remitting multiple sclerosis (MS) have been developed and released to market. These drugs, to varying degrees, reduced the frequency of MS relapses, the accumulation of lesions on MRI, and the progression of disability in randomised controlled trials with follow-up of 2–3 years. The first generation of treatments, beta interferons and glatiramer acetate, also delay a second relapse and thus the risk of conversion to clinically definite MS in patients with a first clinical demyelinating event. (Source: Lancet Neurology)

Continue reading:  

[Comment] New treatments for multiple sclerosis: at what long-term risk?

Leave a Comment

More from category

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]